专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019014513A1 TAM KINASE INHIBITORS 审中-公开
公开(公告)号：WO2019014513A1
公开(公告)日：2019-01-17
申请号：PCT/US2018/041928
申请日：2018-07-13
申请人： SYROS PHARMACEUTICALS, INC.
发明人： ZHANG, Yi , AUSTGEN, Kathryn , CHUAQUI, Claudio Edmundo , MALOJCIC, Goran , SINKO, William , CIBLAT, Stephane , JAMES, Clint , GUAN, Huiping Amy , SAVOIE, Tracey Lodie
IPC分类号： C07D471/04 , A61K31/4375 , A61K31/4523 , A61K31/519 , A61K31/5377 , A61P35/00
摘要： Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat diseases, such as cancer.

2. 发明申请

WO2018237221A1 IMMUNOGENIC COMPOSITIONS 审中-公开
公开(公告)号：WO2018237221A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/038907
申请日：2018-06-22
申请人： NOSOCOMIAL VACCINE CORPORATION , UNIVERSITY OF MARYLAND, BALTIMORE , AFFINIVAX, INC.
发明人： AMBROSINO, Donna , BROERING, Teresa J. , CROSS, Alan , MALLEY, Richard , MICHON, Francis , SIBER, George, Rainer , SIMON, Raphael , TENNANT, Sharon
IPC分类号： A61K47/64 , A61K39/104 , A61K39/108 , C07K14/195 , C07K14/21 , C07K14/26
摘要： Technologies for the prevention and/or treatment of nosocomial infections.

3. 发明申请

WO2017177167A1 RARA AGONISTS FOR THE TREATMENT OF AML AND MDS 审中-公开
标题翻译： RARA致力于治疗AML和MDS
公开(公告)号：WO2017177167A1
公开(公告)日：2017-10-12
申请号：PCT/US2017/026657
申请日：2017-04-07
申请人： SYROS PHARMACEUTICALS, INC.
发明人： MCKEOWN, Michael Robert , FIORE, Christopher , EATON, Matthew Lucas , LEE, Emily Payton , FRITZ, Christian
IPC分类号： A61K31/192 , A61K31/167 , A61K31/232 , A61K31/235 , A61K31/25 , A61K31/353 , A61K31/40 , A61K31/4025 , A61K31/4155 , A61K31/426 , A61K31/44 , A61K31/4436 , A61K31/498 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/573 , A61K31/69 , A61K31/695 , A61K31/704 , A61K31/706 , A61K31/7068 , A61K33/24 , A61K33/36 , A61K45/06 , A61P35/00 , A61P35/02 , A61P35/04 , G01N33/48
摘要： Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists. The methods may comprise administering RARA agonists to patient populations.
摘要翻译：本文描述了定义对RARA激动剂敏感的细胞群体并鉴定将受益于RARA激动剂治疗的患者群体的方法。该方法可以包括将RARA激动剂施用于患者群体。

4. 发明申请

WO2017177167A4 RARA AGONISTS FOR THE TREATMENT OF AML AND MDS 审中-公开
公开(公告)号：WO2017177167A4
公开(公告)日：2017-10-12
申请号：PCT/US2017/026657
申请日：2017-04-07
申请人： SYROS PHARMACEUTICALS, INC.
发明人： MCKEOWN, Michael Robert , FIORE, Christopher , EATON, Matthew Lucas , LEE, Emily Payton , FRITZ, Christian
IPC分类号： A61K31/192 , A61K31/167 , A61K31/232 , A61K31/235 , A61K31/25 , A61K31/353 , A61K31/40 , A61K31/4025 , A61K31/4155 , A61K31/426 , A61K31/44 , A61K31/4436 , A61K31/498 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/573 , A61K31/69 , A61K31/695 , A61K31/704 , A61K31/706 , A61K31/7068 , A61K33/24 , A61K33/36 , A61K45/06 , A61P35/00 , A61P35/02 , A61P35/04 , G01N33/48
摘要： Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists. The methods may comprise administering RARA agonists to patient populations.

5. 发明申请

WO2016070156A3 C1 ESTERASE INHIBITOR FUSION PROTEINS AND USES THEREOF 审中-公开
标题翻译： C1酯酶抑制剂融合蛋白及其用途
公开(公告)号：WO2016070156A3
公开(公告)日：2016-05-06
申请号：PCT/US2015/058521
申请日：2015-10-31
申请人： SHIRE HUMAN GENETIC THERAPIES, INC.
发明人： NORTON, Angela , PAN, Clark , ISKENDERIAN, Andrea , STRACK-LOGUE, Bettina
IPC分类号： C07K14/81
摘要： The present invention provides, among other things, methods and compositions for treating complement mediated disease, in particular, chronic diseases requiring prophylactic and/or maintenance treatment. In one aspect, C1-INH fusion proteins having longer half-life than native plasma-derived C1-INH are provided. In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to a complement-mediated disease, an effective amount of a recombinant C1-INH fusion protein such that at least one symptom or feature of said complement-mediated disease is prevented and/or reduced in intensity, severity, or frequency.
摘要翻译：本发明提供了用于治疗补体介导的疾病，特别是需要预防和/或维持治疗的慢性疾病的方法和组合物。一方面，提供了具有比天然血浆衍生的C1-INH更长的半衰期的C1-INH融合蛋白。在一些实施方案中，根据本发明的方法包括向患有或易患补体介导的疾病的个体施用有效量的重组C1-INH融合蛋白，使得所述的至少一种症状或特征补体介导的疾病在强度，严重程度或频率方面受到预防和/或降低。

6. 发明申请

WO2016049385A1 METHODS AND COMPOSITIONS FOR CANCER TREATMENT AND TREATMENT SELECTION 审中-公开
标题翻译：癌症治疗和治疗选择的方法和组合
公开(公告)号：WO2016049385A1
公开(公告)日：2016-03-31
申请号：PCT/US2015/052074
申请日：2015-09-24
申请人： APELLIS PHARMACEUTICALS, INC.
发明人： FRANCOIS, Cedric
IPC分类号： C12Q1/68 , A61K38/00
CPC分类号： A61K39/39558 , A61K38/1709 , A61K45/06 , A61K47/10 , C07K16/2818 , C07K16/2827 , C07K2317/76 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , G01N33/57492
摘要： In some aspects, the disclosure provides methods of treating cancer or an infection. In some aspects, the disclosure provides methods of enhancing the efficacy of treatment with an immune checkpoint inhibitor. In some embodiments the methods comprise administering a complement inhibitor and an immune checkpoint inhibitor to a subject with cancer or an infection. In some aspects, the disclosure provides methods of identifying a subject who is an appropriate candidate for treatment with an immune checkpoint inhibitor. In some aspects, the disclosure provides methods of identifying a subject who is an appropriate candidate for treatment with an immune checkpoint inhibitor and a complement inhibitor. In some embodiments the methods comprise determining whether the subject is an appropriate candidate for treatment with an immune checkpoint inhibitor and a complement inhibitor based on an assay of a complement system biomarker in the subject or in a sample obtained from the subject.
摘要翻译：在一些方面，本公开提供了治疗癌症或感染的方法。在一些方面，本公开提供了用免疫检查点抑制剂增强治疗功效的方法。在一些实施方案中，所述方法包括向患有癌症或感染的受试者施用补体抑制剂和免疫检查点抑制剂。在一些方面，本公开提供了鉴定作为免疫检查点抑制剂治疗的适当候选物的受试者的方法。在一些方面，本公开提供了鉴定作为免疫检查点抑制剂和补体抑制剂的治疗的适当候选物的受试者的方法。在一些实施方案中，所述方法包括基于受试者中补体系统生物标志物的测定或从受试者获得的样品中确定受试者是否是用免疫检查点抑制剂和补体抑制剂治疗的适当候选物。

7. 发明申请

WO2016077693A1 HYBRID DAIRY CATTLE AND SYSTEMS FOR MAXIMIZING HYBRID ADVANTAGE 审中-公开
标题翻译：混合奶酪和系统，以最大限度地发挥混合优势
公开(公告)号：WO2016077693A1
公开(公告)日：2016-05-19
申请号：PCT/US2015/060576
申请日：2015-11-13
申请人： GENUS PLC
发明人： LIGHTNER, Jon , WILLIAMS, Richard
IPC分类号： A01K67/02 , A61D19/02 , A61K35/52 , A61K35/54
CPC分类号： A01K67/02 , A61D19/02 , A61D19/04 , A61K35/52 , A61K35/54
摘要： Systems for selecting, generating, and breeding hybrid dairy cattle are described, as are methods for maintaining herds of hybrid cattle.
摘要翻译：描述了用于选择，产生和繁殖杂交奶牛的系统，以及用于保持杂种牛群的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式